![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RPS26 |
Gene summary for RPS26 |
![]() |
Gene information | Species | Human | Gene symbol | RPS26 | Gene ID | 6231 |
Gene name | ribosomal protein S26 | |
Gene Alias | DBA10 | |
Cytomap | 12q13.2 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | A0A024RB14 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6231 | RPS26 | GSM4909280 | Human | Breast | Precancer | 1.89e-05 | -7.96e-01 | 0.0305 |
6231 | RPS26 | GSM4909281 | Human | Breast | IDC | 6.13e-20 | -3.80e-01 | 0.21 |
6231 | RPS26 | GSM4909282 | Human | Breast | IDC | 1.04e-38 | -5.69e-01 | -0.0288 |
6231 | RPS26 | GSM4909286 | Human | Breast | IDC | 1.62e-13 | 2.75e-01 | 0.1081 |
6231 | RPS26 | GSM4909287 | Human | Breast | IDC | 1.20e-20 | -6.08e-01 | 0.2057 |
6231 | RPS26 | GSM4909292 | Human | Breast | IDC | 7.15e-03 | -6.49e-01 | 0.1236 |
6231 | RPS26 | GSM4909293 | Human | Breast | IDC | 2.78e-05 | 2.24e-01 | 0.1581 |
6231 | RPS26 | GSM4909294 | Human | Breast | IDC | 1.64e-53 | 4.40e-01 | 0.2022 |
6231 | RPS26 | GSM4909295 | Human | Breast | IDC | 7.51e-31 | 4.49e-01 | 0.0898 |
6231 | RPS26 | GSM4909296 | Human | Breast | IDC | 7.26e-71 | 5.28e-01 | 0.1524 |
6231 | RPS26 | GSM4909297 | Human | Breast | IDC | 9.49e-17 | -9.89e-03 | 0.1517 |
6231 | RPS26 | GSM4909298 | Human | Breast | IDC | 3.58e-06 | -1.80e-01 | 0.1551 |
6231 | RPS26 | GSM4909299 | Human | Breast | IDC | 3.49e-06 | 2.35e-01 | 0.035 |
6231 | RPS26 | GSM4909300 | Human | Breast | IDC | 6.31e-08 | -5.41e-01 | 0.0334 |
6231 | RPS26 | GSM4909301 | Human | Breast | IDC | 2.48e-04 | -2.08e-01 | 0.1577 |
6231 | RPS26 | GSM4909303 | Human | Breast | IDC | 7.93e-04 | 2.80e-01 | 0.0438 |
6231 | RPS26 | GSM4909305 | Human | Breast | IDC | 1.15e-03 | 1.82e-01 | 0.0436 |
6231 | RPS26 | GSM4909308 | Human | Breast | IDC | 2.73e-06 | -1.07e-01 | 0.158 |
6231 | RPS26 | GSM4909309 | Human | Breast | IDC | 1.20e-14 | -5.80e-01 | 0.0483 |
6231 | RPS26 | GSM4909311 | Human | Breast | IDC | 4.04e-59 | 3.19e-01 | 0.1534 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0033119113 | Thyroid | PTC | negative regulation of RNA splicing | 22/5968 | 25/18723 | 9.00e-09 | 2.18e-07 | 22 |
GO:00427699 | Thyroid | PTC | DNA damage response, detection of DNA damage | 10/5968 | 13/18723 | 1.11e-03 | 6.51e-03 | 10 |
GO:0002181210 | Thyroid | goiters | cytoplasmic translation | 73/497 | 148/18723 | 1.65e-75 | 6.83e-72 | 73 |
GO:0043484210 | Thyroid | goiters | regulation of RNA splicing | 19/497 | 148/18723 | 1.44e-08 | 1.49e-06 | 19 |
GO:000838029 | Thyroid | goiters | RNA splicing | 31/497 | 434/18723 | 6.49e-07 | 3.95e-05 | 31 |
GO:0033119210 | Thyroid | goiters | negative regulation of RNA splicing | 6/497 | 25/18723 | 3.91e-05 | 1.38e-03 | 6 |
GO:000838034 | Thyroid | ATC | RNA splicing | 270/6293 | 434/18723 | 7.50e-35 | 1.19e-31 | 270 |
GO:000218135 | Thyroid | ATC | cytoplasmic translation | 121/6293 | 148/18723 | 1.41e-33 | 1.49e-30 | 121 |
GO:004348435 | Thyroid | ATC | regulation of RNA splicing | 100/6293 | 148/18723 | 2.75e-17 | 2.72e-15 | 100 |
GO:003311935 | Thyroid | ATC | negative regulation of RNA splicing | 21/6293 | 25/18723 | 3.02e-07 | 4.52e-06 | 21 |
GO:004276914 | Thyroid | ATC | DNA damage response, detection of DNA damage | 10/6293 | 13/18723 | 1.77e-03 | 8.71e-03 | 10 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPS26 | SNV | Missense_Mutation | c.329N>T | p.Pro110Leu | p.P110L | P62854 | protein_coding | deleterious(0.02) | probably_damaging(0.975) | TCGA-F5-6864-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
RPS26 | SNV | Missense_Mutation | c.203A>G | p.Tyr68Cys | p.Y68C | P62854 | protein_coding | tolerated(0.05) | benign(0.286) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RPS26 | SNV | Missense_Mutation | c.190N>T | p.Leu64Phe | p.L64F | P62854 | protein_coding | deleterious(0.04) | possibly_damaging(0.532) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
RPS26 | SNV | Missense_Mutation | novel | c.299G>A | p.Arg100Gln | p.R100Q | P62854 | protein_coding | tolerated(0.19) | possibly_damaging(0.553) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
RPS26 | SNV | Missense_Mutation | novel | c.23N>G | p.Asn8Ser | p.N8S | P62854 | protein_coding | tolerated(0.08) | benign(0) | TCGA-49-4490-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
RPS26 | SNV | Missense_Mutation | c.123T>G | p.Ile41Met | p.I41M | P62854 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-66-2727-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RPS26 | insertion | In_Frame_Ins | novel | c.274_275insAATACCTGA | p.Arg92delinsGlnTyrLeuSer | p.R92delinsQYLS | P62854 | protein_coding | TCGA-ET-A40R-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |